Back to Trials
NCT07609394Recruiting

Duchenne Electronic Health Record Study

The Duchenne Registry

Start Date

12/1/2022

Completion Date

12/1/2072

Summary

This study aims to collect retrospective and prospective, long-term data of patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer. At select clinics across the United States, electronic health record (EHR) data from consented patients will be pushed into PPMD's Duchenne Outcomes Research Interchange (the Interchange), where the EHR data can be combined with patient-reported data from The Duchenne Registry. By combining this data in a central hub, we will gain a more complete picture of Duchenne and Becker muscular dystrophy, allowing researchers and clinicians to develop treatments faster and to improve and refine the standards of care for Duchenne and Becker. The ultimate goal is to optimize function, quality of life, and survival of Duchenne and Becker patients. EHR data collected will be fully identifiable retrospective data for core clinical data elements going back ten years (as available) from the date of consent; going back one year for retrospective clinical notes from the date of consent; and prospectively collecting both core clinical data elements and clinical notes. Information collected will align with the FHIR U.S. core data elements, also known as the Common Clinical Data Set. PPMD partnered with Prometheus Research (an IQVIA company), an industry leader in health data informatics, to launch both the EHR Study and the Interchange. All data is stored securely and in accordance with strict industry standards and patient privacy laws. Participation in the EHR data extraction is voluntary, and a patient can withdraw consent at any time.

Eligibility Criteria

Age Range: No minimum to No maximum

Inclusion Criteria: * Duchenne or Becker muscular dystrophy or female carrier * Must be a patient at an institution that has an established EHR integration set up with PPMD's Interchange * Must provide consent to have their EHR data pushed to the Interchange and linked to existing Registry data, if applicable Exclusion Criteria: * Individuals with other forms of muscular dystrophy * Individuals who do not provide consent Individuals with Duchenne/Becker who have severe mobility/strength issues need to provide consent and participate with assistance from a caregiver. Adults with communication impairments and/or intellectual disabilities (considered the "decisionally impaired" group for purposes of this study) will be able to consent with the assistance of the adults who are designated Legally Authorized Representative (LAR). Without assistance, this group will be excluded from participation because the consent process.

Interventions

OTHER

Observational study with patients who may be treated with various disease-modifying therapies

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Duchenne Muscular Dystrophy (DMD)Becker Muscular DystrophyDystrophinopathyDystrophinopathy Symptomatic Female Carrier

Locations

Arkansas Children's Hospital

Little Rock, Arkansas 72202

United States

UC Davis Health

Sacramento, California 95817

United States

Children's Hospital Colorado

Aurora, Colorado 80045

United States

Yale Children's Hospital

New Haven, Connecticut 06511

United States

Children's National Medical Center

Washington D.C., District of Columbia 20010

United States

University of Iowa Health Care

Iowa City, Iowa 52242

United States

Duke University Medical Center

Durham, North Carolina 27710

United States

UT Southwestern Medical Center

Dallas, Texas 75390

United States

Primary Children's Hospital

Salt Lake City, Utah 84113

United States

University of Utah Health

Salt Lake City, Utah 84132

United States